Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis

Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study)

(2020) Manjunath Krishnappa et al.   Cardiovascular Diabetology

The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease

(2020) Divya P. Kumar et al.   Scientific Reports

Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study

(2020) Omesh Goyal et al.   Scientific Reports

Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

(2018) Zobair M. Younossi et al.   HEPATOLOGY

Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From “two hit theory” to “multiple hit model”

(2018) Yan-Lan Fang et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Pivotal Role of TNF-α in the Development and Progression of Nonalcoholic Fatty Liver Disease in a Murine Model

(2017) Satomi Kakino et al.   HORMONE AND METABOLIC RESEARCH

A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease

(2017) Zhonge Chen et al.   Lipids in Health and Disease

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models

(2017) Mukul R. Jain et al.   LIVER INTERNATIONAL

The role of leptin in diabetes: metabolic effects

(2016) Thomas H. Meek et al.   DIABETOLOGIA

Effects of combined PPAR-γ and PPAR-α agonist therapy on fructose induced NASH in rats: Modulation of gene expression

(2016) Enas A. Abd El-Haleim et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Molecular Pathogenesis of NASH

(2016) Alessandra Caligiuri et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease

(2016) Manoela Mota et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)

(2016) Elena Buzzetti et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD

(2016) Barbara Gross et al.   Nature Reviews Endocrinology

Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis

(2015) Stergios A. Polyzos et al.   DIABETOLOGIA

Oleoylethanolamide, an endogenous PPAR-α ligand, attenuates liver fibrosis targeting hepatic stellate cells

(2015) Ling Chen et al.   Oncotarget

Establishment of a General NAFLD Scoring System for Rodent Models and Comparison to Human Liver Pathology

(2014) Wen Liang et al.   PLoS One

TGF-β in wound healing: a review

(2014) H.E. Douglas   Journal of Wound Care

Cytokines in alcoholic liver disease

(2012) Leon An et al.   ARCHIVES OF TOXICOLOGY

Mitochondrial dysfunction in white adipose tissue

(2012) Christine M. Kusminski et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Role of cytokines and chemokines in non-alcoholic fatty liver disease

(2012) Vincent Braunersreuther   WORLD JOURNAL OF GASTROENTEROLOGY

Adiponectin reduces connective tissue growth factor in human hepatocytes which is already induced in non-fibrotic non-alcoholic steatohepatitis

(2011) Roland Walter et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Growth hormone, dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis: an endocrine signature for advanced fibrosis in obese patients

(2011) Edith Koehler et al.   LIVER INTERNATIONAL

Role of serum adiponectin level in the development of liver cirrhosis in patients with hepatitis C virus

(2010) Hatem Abdel Latif et al.   CLINICAL AND EXPERIMENTAL MEDICINE

Monocyte chemoattractant protein-1 deficiency does not affect steatosis or inflammation in livers of mice fed a methionine–choline-deficient diet

(2010) Karen M Kassel et al.   LABORATORY INVESTIGATION

Kupffer Cells Mediate Leptin-Induced Liver Fibrosis

(2009) Jianhua Wang et al.   GASTROENTEROLOGY

Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients

(2008) Y. Miyazaki et al.   DIABETES OBESITY & METABOLISM